keyword
MENU ▼
Read by QxMD icon Read
search

Nsclc molecular markers

keyword
https://www.readbyqxmd.com/read/29145450/enhanced-expression-of-cell-surface-b-cell-receptor-associated-protein-31-contributes-to-poor-survival-of-non-small-cell-lung-carcinoma-cells
#1
Se-Ri Seo, Hyun Min Lee, Hong Seo Choi, Won-Tae Kim, Eun-Wie Cho, Chun Jeih Ryu
B-cell receptor-associated protein 31 (BAP31) is an endoplasmic reticulum (ER) membrane protein which plays a role as a molecular chaperone for the newly synthesized transmembrane proteins. BAP31 is also an important apoptosis regulator for extrinsic apoptosis induction in the ER membrane. Recent studies have shown that BAP31 is also expressed on the surface of embryonic stem cells. However, the function of cell surface BAP31 (csBAP31) still remains unclarified. In an attempt to search for surface markers on tumorspheres, here, we generated monoclonal antibodies (MAbs) against the sphere cells from the non-small cell lung carcinoma cell (NSCLC) line A549...
2017: PloS One
https://www.readbyqxmd.com/read/29139039/genetic-screening-and-molecular-characterization-of-met-alterations-in-non-small-cell-lung-cancer
#2
M Saigi, A McLeer-Florin, E Pros, E Nadal, E Brambilla, M Sanchez-Cespedes
PURPOSE: Aberrant activation of MET as a result of exon 14-skipping (METex14) mutations or gene amplification is an oncogenic mechanism in non-small cell lung carcinoma (NSCLC) and a potential therapeutic target. The purpose of this study was to characterize MET alterations in a cohort of NSCLC patients treated with surgery. METHODS AND PATIENTS: 157 NSCLCs of various histopathologies, including pulmonary sarcomatoid carcinomas (PSC), were tested for MET alterations...
November 14, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29137415/ubiquitin-conjugating-enzyme-e2-l3-promoted-tumor-growth-of-nsclc-through-accelerating-p27kip1-ubiquitination-and-degradation
#3
Xingjie Ma, Junjie Zhao, Fan Yang, Haitao Liu, Weibo Qi
The molecular pathogenesis of human lung cancer has not been completely clarified. Here, we reported that UBE2L3, a member of the ubiquitin-conjugating enzymes (E2s), were overexpressed in non-small-cell lung cancer (NSCLC) tissues compared with the non-tumor tissues. High expression of UBE2L3 was correlated with advanced tumor stage and adverse outcomes. Knockdown of UBE2L3 inhibited NSCLC cell growth while ectopic expression of UBE2L3 promoted NSCLC cell growth in a cell cycle dependent manner. The results of subcutaneous tumor xenograft studies revealed that knockdown of UBE2L3 attenuated the in vivo tumor growth...
October 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/29123964/a-novel-bifunctional-anti-pd-l1-tgf-%C3%AE-trap-fusion-protein-m7824-efficiently-reverts-mesenchymalization-of-human-lung-cancer-cells
#4
Justin M David, Charli Dominguez, Kristen K McCampbell, James L Gulley, Jeffrey Schlom, Claudia Palena
Mesenchymalization is a cellular and molecular program in which epithelial cells progressively lose their well-differentiated phenotype and adopt mesenchymal characteristics. Tumor mesenchymalization occurs during the progression of cancer to metastatic disease, and is also associated with resistance to multiple therapeutics, including killing by cytotoxic immune cells. Furthermore, tumor cells can evade immune destruction by upregulating the checkpoint molecule PD-L1, and emerging research has found higher PD-L1 expression in mesenchymalized tumors...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/29116073/-differential-expression-of-an-ensemble-of-the-key-genes-involved-in-cell-cycle-regulation-in-lung-cancer
#5
G S Krasnov, G A Puzanov, A V Kudryavtseva, A A Dmitriev, A D Beniaminov, T T Kondratieva, V N Senchenko
Targeted cancer therapy directed at individual targets is often accompanied by the rapid development of drug resistance. The development of a new generation of antitumor drugs involves the search for many targets simultaneously to block or, conversely, restore their activity. In this regard, simultaneous analysis of gene expression in a complex network of interactions, primarily cell cycle control elements, is relevant for the search of specific molecular markers for the differential diagnosis of adenocarcinoma (ADC) and squamous cell lung cancer (SCC), as well as new targets for therapy...
September 2017: Molekuliarnaia Biologiia
https://www.readbyqxmd.com/read/29097801/efhd2-promotes-epithelial-to-mesenchymal-transition-and-correlates-with-postsurgical-recurrence-of-stage-i-lung-adenocarcinoma
#6
Chi-Chen Fan, Wei-Chung Cheng, Yu-Chuen Huang, Yuh-Pyng Sher, Nia-Jhen Liou, Yu-Chuan Chien, Pei-Shan Lin, Pei-Syuan Lin, Chung-Hsuan Chen, Wei-Chao Chang
Surgery is the only curative treatment for early-stage non-small cell lung cancer (NSCLC) patients. However, approximately one-third of these patients develop recurrence, which remains the main cause of mortality in the postsurgical treatment of NSCLC. Many molecular markers have been proposed to predict recurrence of early-stage disease, but no marker has demonstrated sufficient reliability for clinical application. In the present study, the novel protein EF-hand domain-containing protein D2 (EFHD2) was identified as expressed in highly metastatic tumor cells...
November 6, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29090068/altered-mir-223-expression-in-sputum-for-diagnosis-of-non-small-cell-lung-cancer
#7
Abouzar Bagheri, Hamid Reza Khorram Khorshid, Seyed Javad Mowla, Hassan Ali Mohebbi, Azam Mohammadian, Mehdi Yaseri, Masoud Solaymani-Dodaran, Masih Sherafatian, Mahmood Tavallaie
BACKGROUND: Diagnosis of Non-small Cell Lung Cancer (NSCLC) at an early stage is a daunting challenge due to the deficiency of specific noninvasive markers. MicroRNAs (miRNAs) play important roles in the initiation and progression of NSCLC. Measuring miRNA expression levels could provide a potential approach for the diagnosis of NSCLC. Our goals were to examine miR-223, miR-212, miR-192, miR-3074, SNORD33 and SNORD37 expression levels in tissue and sputum of NSCLC patients and cancer free subjects for molecular diagnosis of NSCLC...
October 2017: Avicenna Journal of Medical Biotechnology
https://www.readbyqxmd.com/read/29066916/mutation-analysis-and-copy-number-alterations-of-kif23-in-non-small-cell-lung-cancer-exhibiting-kif23-over-expression
#8
Ann-Louise Vikberg, Tõnu Vooder, Kaie Lokk, Tarmo Annilo, Irina Golovleva
KIF23 was recently suggested to be a potential molecular target for the treatment of lung cancer. This proposal is based on elevated expression of KIF23 in several tumors affecting breast, lung, brain, and liver, and also on the presence of KIF23 mutations in melanoma and colorectal cancer. Recently, we identified a mutation in the KIF23 gene causing a rare hereditary form of dyserythropoietic anemia (CDA III) with predisposition to blood cancer. We suggested that KIF23 overexpression in tumors might be due to the presence of activating somatic mutations, and therefore, mutation screening of the KIF23 in 15 non-small-cell lung cancer (NSCLC) cases with elevated expression level of KIF23 was undertaken...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29057231/prioritizing-molecular-markers-to-test-for-in-the-initial-workup-of-advanced-non-small-cell-lung-cancer-wants-versus-needs
#9
REVIEW
Howard West
The current standard of care for molecular marker testing in patients with advanced non-small cell lung cancer (NSCLC) has been evolving over several years and is a product of the quality of the evidence supporting a targeted therapy for a specific molecular marker, the pre-test probability of that marker in the population, and the magnitude of benefit seen with that treatment. Among the markers that have one or more matched targeted therapies, only a few are in the subset for which they should be considered as most clearly worthy of prioritizing to detect in the first line setting in order to have them supplant other first line alternatives, and in only a subset of patients, as defined currently by NSCLC histology...
September 2017: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29050314/applicability-of-graded-prognostic-assessment-of-lung-cancer-using-molecular-markers-to-lung-adenocarcinoma-patients-with-brain-metastases
#10
Hongwei Li, Jianhong Lian, Songyan Han, Weili Wang, Haixia Jia, Jianzhong Cao, Xiaqin Zhang, Xin Song, Sufang Jia, Jiwei Ren, Weihua Yang, Yanfeng Xi, Shengmin Lan
Several scoring systems are available to estimate prognosis and assist in selecting treatment methods for non-small cell lung cancer (NSCLC) patients with brain metastasis, including recursive partitioning analysis (RPA), basic score for brain metastases (BS-BM), and diagnosis-specific graded prognostic assessment (DS-GPA). Lung-molGPA is an update of the DS-GPA that incorporates EGFR and/or ALK mutation status. The present study tested the applicability of these four indexes in 361 lung adenocarcinoma patients with brain metastasis...
September 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/29039479/mdig-suppresses-epithelial-mesenchymal-transition-and-inhibits-the-invasion-and-metastasis-of-non%C3%A2-small-cell-lung-cancer-via-regulating-gsk-3%C3%AE-%C3%AE-catenin-signaling
#11
Feng Geng, Zhanshi Jiang, Xiaogang Song, Haomin Zhou, Hongwen Zhao
Mineral dust-induced gene (mdig) can inhibit the invasion and metastasis of A549 cells. The main purpose of this study was to explore the molecular mechanism underlying the inhibitory effect of mdig on cell invasion and metastasis. Mdig-knockdown and mdig-overexpressing A549 cells and an mdig-overexpressing human umbilical vein endothelial cell (HUVEC) line were constructed using lentiviral vectors, and western blot analysis was performed to verify the silencing and overexpression of the mdig protein. A Transwell invasion assay was used to detect the invasive abilities of each experimental group, and Transwell migration and scratch assays were used to detect cell migration ability...
October 12, 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/28959367/elacridar-a-third-generation-abcb1-inhibitor-overcomes-resistance-to-docetaxel-in-non-small-cell-lung-cancer
#12
Haiyang Chen, Kazuhiko Shien, Ken Suzawa, Kazunori Tsukuda, Shuta Tomida, Hiroki Sato, Hidejiro Torigoe, Mototsugu Watanabe, Kei Namba, Hiromasa Yamamoto, Junichi Soh, Hiroaki Asano, Shinichiro Miyoshi, Shinichi Toyooka
Docetaxel is a third-generation chemotherapeutic drug that is widely used in the treatment of patients with non-small cell lung cancer (NSCLC). However, the majority of patients with NSCLC eventually acquire resistance to the treatment. In the present study, the mechanism of acquired resistance to docetaxel treatment in lung cancer cells was investigated. The three NSCLC cell lines, H1299 with wild-type epidermal growth factor receptor (EGFR), EGFR-mutant HCC4006 and HCC827, and experimentally established docetaxel-resistant (DR) cells, H1299-DR, HCC827-DR, and HCC4006-DR were used with stepwise increases in concentrations of docetaxel...
October 2017: Oncology Letters
https://www.readbyqxmd.com/read/28946563/trim66-expression-in-non-small-cell-lung-cancer-a-new-predictor-of-prognosis
#13
Yan Ma, Huan-Yu Dai, Feng Zhang, Da Zhao
OBJECTIVE: The tripartite motif-containing protein (TRIM) family is involved in important biological processes such as the cell cycle, cell apoptosis, and innate immunity of virus. This study aimed to investigate TRIM66 expression and its predictive role in non-small cell lung cancer (NSCLC) patients. METHODS: We detected the expression levels of TRIM66 protein and TRIM66 mRNA in NSCLC tissues, and evaluated the prognostic role of TRIM66 in NSCLC. RESULTS: TRIMM66 was highly expressed in NSCLC tissues compared with normal paracancerous tissues (P= 0...
September 7, 2017: Cancer Biomarkers: Section A of Disease Markers
https://www.readbyqxmd.com/read/28927083/expression-of-thymidylate-synthase-predicts-clinical-outcomes-of-s-1-based-chemotherapy-in-squamous-cell-lung-cancer
#14
Yuichiro Honma, Shinsaku Togo, Kazue Shimizu, Miniwan Tulafu, Takuo Hayashi, Toshimasa Uekusa, Shigeru Tominaga, Kenji Kido, Yuichi Fujimoto, Yukiko Nanba, Kazuya Takamochi, Shiaki Oh, Kenji Suzuki, Kazuhisa Takahashi
Non-small cell lung cancer (NSCLC) patients with squamous cell carcinoma (SCC) histology have limited chemotherapeutic options. Treatment with S-1 combined with carboplatin (CBDCA) has been shown to provide a significant survival benefit in SCC patients compared with treatment with combined CBDCA and paclitaxel. The aim of the present study was to investigate the association between the expression of molecular markers related to the pharmacological action of S-1, including thymidylate synthase (TS), orotate phosphoribosyltransferase (OPRT) and dihydropyrimidine dehydrogenase (DPD), and the clinical efficacy of S-1-based chemotherapy in SCC patients...
September 2017: Oncology Letters
https://www.readbyqxmd.com/read/28920053/smoking-and-lung-cancer-a-geo-regional-perspective
#15
REVIEW
Zahraa Rahal, Shaza El Nemr, Ansam Sinjab, Hassan Chami, Arafat Tfayli, Humam Kadara
Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) represents the most frequently diagnosed subtype of this morbid malignancy. NSCLC is causally linked to tobacco consumption with more than 500 million smokers worldwide at high risk for this fatal malignancy. We are currently lagging in our knowledge of the early molecular (e.g., genomic) effects of smoking in NSCLC pathogenesis that would constitute ideal markers for early detection. This limitation is further amplified when considering the variable etiologic factors in NSCLC pathogenesis among different regions around the globe...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28881794/enhanced-efficacy-of-akt-and-fak-kinase-combined-inhibition-in-squamous-cell-lung-carcinomas-with-stable-reduction-in-pten
#16
Andrea Cavazzoni, Silvia La Monica, Roberta Alfieri, Andrea Ravelli, Nele Van Der Steen, Rocco Sciarrillo, Denise Madeddu, Costanza Anna Maria Lagrasta, Federico Quaini, Mara Bonelli, Claudia Fumarola, Daniele Cretella, Graziana Digiacomo, Marcello Tiseo, Godefridus J Peters, Andrea Ardizzoni, Pier Giorgio Petronini, Elisa Giovannetti
Squamous cell lung carcinoma (SCC) accounts for 30% of patients with NSCLC and to date, no molecular targeted agents are approved for this type of tumor. However, recent studies have revealed several oncogenic mutations in SCC patients, including an alteration of the PI3K/AKT pathway, i.e. PI3K point mutations and amplification, AKT mutations and loss or reduced PTEN expression. Prompted by our observation of a correlation between PTEN loss and FAK phosphorylation in a cohort of patients with stage IV SCC, we evaluated the relevance of PTEN loss in cancer progression as well as the efficacy of a new combined treatment with the pan PI3K inhibitor buparlisip and the FAK inhibitor defactinib...
August 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/28862415/exploring-adjuvant-epidermal-growth-factor-receptor-inhibition-in-non-small-cell-lung-cancer
#17
REVIEW
Giulia M Stella, Davide Piloni
Lung cancer is among the most important causes of death worldwide. Despite the relevant progresses in the personalized approach to lung cancer, patients' survival is still poor. Only a minor fraction of patients can be addressed to surgery for radical tumor removal. Adjuvant chemotherapy is currently recommended for resected stages II and III patients although it is known that it can modestly contribute to survival prolongation. A better identification of molecular markers, predictive of adjuvant chemo response is now mandatory, in order to reduce useless toxicities and identify those patients who could really benefit...
June 2017: Minerva Medica
https://www.readbyqxmd.com/read/28819856/fiber-optic-array-scanning-technology-fast-for-detection-and-molecular-characterization-of-circulating-tumor-cells
#18
Zheng Ao, Xiaohe Liu
Circulating tumor cell (CTC) as an important component in "liquid biopsy" holds crucial clinical relevance in cancer prognosis, treatment efficiency evaluation, prediction and potentially early detection. Here, we present a Fiber-optic Array Scanning Technology (FAST) that enables antigen-agnostic, size-agnostic detection of CTC. By immunofluorescence staining detection of a combination of a panel of markers, FAST technology can be applied to detect rare CTC in non-small cell lung cancer (NSCLC) setting with high sensitivity and specificity...
2017: Methods in Molecular Biology
https://www.readbyqxmd.com/read/28771186/epithelial-to-mesenchymal-transition-and-micrornas-in-lung-cancer
#19
REVIEW
Antoine Legras, Nicolas Pécuchet, Sandrine Imbeaud, Karine Pallier, Audrey Didelot, Hélène Roussel, Laure Gibault, Elizabeth Fabre, Françoise Le Pimpec-Barthes, Pierre Laurent-Puig, Hélène Blons
Despite major advances, non-small cell lung cancer (NSCLC) remains the major cause of cancer-related death in developed countries. Metastasis and drug resistance are the main factors contributing to relapse and death. Epithelial-to-mesenchymal transition (EMT) is a complex molecular and cellular process involved in tissue remodelling that was extensively studied as an actor of tumour progression, metastasis and drug resistance in many cancer types and in lung cancers. Here we described with an emphasis on NSCLC how the changes in signalling pathways, transcription factors expression or microRNAs that occur in cancer promote EMT...
August 3, 2017: Cancers
https://www.readbyqxmd.com/read/28743242/association-between-the-xrcc1-polymorphisms-and-clinical-outcomes-of-advanced-nsclc-treated-with-platinum-based-chemotherapy-a-meta-analysis-based-on-the-prisma-statement
#20
Dan-Juan Li, Dong Xiao
BACKGROUND: Base excision repair (BER) pathway is a DNA repair pathway that is important in carcinogenesis and in response to DNA-damaging chemotherapy. XRCC1 is one of important molecular markers for BER. So far, the role of XRCC1 polymorphisms with clinical outcomes of advanced NSCLC treated with platinum-based chemotherapy is inconclusive. To explore the relationship between XRCC1 polymorphisms and platinum-based chemotherapy in advanced NSCLC patients, we performed this meta-analysis...
July 25, 2017: BMC Cancer
keyword
keyword
15359
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"